TITLE

Pharmaceuticals and intellectual property rights: A political economy of the recent policy changes across the developing world and in Turkey

AUTHOR(S)
Vural, ─░pek Eren
PUB. DATE
December 2007
SOURCE
Middle East Technical University Studies in Development;Dec2007, Vol. 34 Issue 2, p337
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This paper explores the sources of the recent policy changes from weaker to stronger intellectual property regimes (IPRs) for pharmaceuticals across the developing world, and in Turkey. Analysing the policy change from a political economy approach, the paper argues that the increased structural power of the transnational capital in the 1980s had been the most important common factor in setting the ground for changes in the IPRs for pharmaceuticals across the developing world. Against the state-centric theories that interpret the policy change primarily as a matter between the nation states from developed and developing countries, the paper contends that the nature and scope of policy outcomes on pharmaceutical IPRs have been shaped by the dynamics of the class struggles across the developing world. The latter argument is supported through an analysis of the Turkish public policy processes and outcomes which resulted in strengthening the IPR for pharmaceuticals. The paper concludes that rather than a mere external imposition on the "Turkish state" by the advanced capitalist countries or the European Union (EU), the policy change in favour of stronger IPRs for pharmaceuticals was sustained and shaped by the Turkish conglomerate capital which pursued reintegration with the transnational capital as a political strategy.
ACCESSION #
31260110

 

Related Articles

  • The patentability of medicinal inventions related to personalized medicine in Japan. Shimbo, Itsuki; Cobden, Andrew; Sumikura, Koichi // Nature Biotechnology;Nov2005, Vol. 23 Issue 11, p1367 

    Reports on the several amendments of the examination guidelines for medicinal inventions in Japan. Possibility of obtaining a patent for a medicinal innovation by specifying the class of patients; Protection of the combinations of medicines and optimization of dosage and frequency of...

  • Pharma patents: India ranks second.  // Siliconindia;Sep2005, Vol. 9 Issue 8, p15 

    Reports on the increasing number of applications for patent of pharmaceutical products in India. Invention of critical life saving drugs by the pharmaceutical companies; Launch of drugs at a frenetic pace in Western countries; Attraction of international attention by the pharmaceutical firms...

  • Drug firms use legal loopholes to safeguard brand names. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);08/05/2000, Vol. 321 Issue 7257, p320 

    Focuses on a report from the National Institute for Health Care Management on the efforts of United States pharmaceutical companies to extend the life of patents for lucrative drugs. How the extension of intellectual property protections prevents the entrance of inexpensive generic drugs into...

  • Patents, Innovation and Access to New Pharmaceuticals. Grabowski, Henry // Journal of International Economic Law;Dec2002, Vol. 5 Issue 4, p849 

    This paper considers the role of intellectual property rights in the development of, and access to, new pharmaceuticals. A number of studies have found patents are significantly more important to pharmaceutical firms in appropriating the benefits from innovation compared with other high tech...

  • Ethical Pharma Companies Fight Generics Head On. Scott, Alex // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article reveals that some ethical pharmaceutical companies have started to challenge the established pricing model for branded pharmaceuticals that go off patent. Merck and Pfizer have each opted to offer major price discounts on leading drugs that recently went off patent, to fight...

  • Report from: India. Nair, A. // Pharmaceutical Technology;Mar2009, Vol. 33 Issue 3, p18 

    The article discusses the condition of pharmaceutical industry's research and development (R&D) sector in India. According to the World Intellectual Property Organization (WIPO), compared with developed countries in terms of drug patent capitalizations, India is far behind due to the global...

  • Litigation Is The Business Model For Generic Drug Maker. Andersen, Steven // Corporate Legal Times;Apr2003, Vol. 13 Issue 137, p24 

    Presents a discussion on the litigation challenges faced by Teva Pharmaceutical Industries Limited, manufacturer of generic drugs, in the U.S. Difficulty of handling international intellectual property function; Description of patents held; Competition with brand name pharmaceutical companies. ...

  • Preface. Reitz, Allen B. // Current Topics in Medicinal Chemistry;Jan2012, Vol. 12 Issue 1, p1 

    The author addresses the changes within the pharmaceutical industry and medicinal chemistry. He notes that 22 of the top 25 selling drugs are generic and lack the composition of matter patent protection that characterizes the early phase of the life cycle for any successful new product launch in...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics